Literature DB >> 16562510

[Melanoma-associated retinopathy with unknown primary site in a Japanese woman].

Koichiro Murayama1, Hiroyasu Takita, Yoshio Kiyohara, Yoshihiko Shimizu, Tetsuya Tsuchida, Shin Yoneya.   

Abstract

BACKGROUND: We report the clinical features of the first case of a Japanese person with melanoma-associated retinopathy. CASE: A 44-year-old woman complained of photopsia and blurred vision in her right eye, and was treated with steroids for uveitis by an ophthalmologist. She was referred to our hospital for further examination. After one month of treatment, she still complained of photopsia in her right eye. The best corrected visual acuity in the right eye was 0.8 and these was sensitivity loss in the central visual field test. Ophthalmoscopy and fluorescein angiography showed some retinal vasculitis in the right eye. A full-field electroretinogram demonstrated a negative-type electroretinogram (ERG) waveform with attenuation of the b-wave amplitude in the right eye. A dark adaptation test revealed sensitivity loss of the rods. The lymph nodes on the right side of her neck were examined and the diagnosis was made of metastic cutaneous melanoma with unknown primary site; her visual dysfunction was diagnosed as melanoma-associated retinopathy. The retinal inflammation improved after steroid treatment, but her visual dysfunction remained. Chemotherapy and an immunotherapy regimen was begun, but 36 months later she died of metastatic melanoma in the lungs.
CONCLUSIONS: A woman treated for uveitis without any prior systemic and ocular diseases was diagnosed with melanoma-associated retinopathy and metastatic melanoma in the cervical lymph nodes of unknown primary origin. The first ocular symptoms were photopsia and blurred vision, not night blindness. ERG was useful for diagnosing this rare ocular condition in an early stage.

Entities:  

Mesh:

Year:  2006        PMID: 16562510

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  6 in total

1.  Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.

Authors:  Monica D Dalal; Catherine W Morgans; Robert M Duvoisin; Elizabeth A Gamboa; Brett G Jeffrey; Sunir J Garg; Chi-Chao Chan; H Nida Sen
Journal:  Ophthalmology       Date:  2013-09-17       Impact factor: 12.079

2.  Melanoma-associated retinopathy associated with intranasal melanoma.

Authors:  Shigeki Machida; Hiroshi Ohguro; Masaru Tateda; Hiroaki Sato; Dajiro Kurosaka
Journal:  Doc Ophthalmol       Date:  2011-05-03       Impact factor: 2.379

3.  Presumed melanoma-associated retinopathy (MAR): a presenting sign of primary small intestinal melanoma?

Authors:  Daniel Rappoport; Hana Leiba
Journal:  Int Ophthalmol       Date:  2012-04-24       Impact factor: 2.031

4.  Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.

Authors:  Wei-Che Hung; Hui-Chen Cheng; An-Guor Wang
Journal:  Doc Ophthalmol       Date:  2022-09-29       Impact factor: 1.854

5.  Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.

Authors:  Juliette Varin; Margaret M Reynolds; Nassima Bouzidi; Sarah Tick; Juliette Wohlschlegel; Ondine Becquart; Christelle Michiels; Olivier Dereure; Robert M Duvoisin; Catherine W Morgans; José-Alain Sahel; Quentin Samaran; Bernard Guillot; José S Pulido; Isabelle Audo; Christina Zeitz
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

6.  Clinical Findings of Melanoma-Associated Retinopathy with anti-TRPM1 Antibody.

Authors:  Yoichiro Shinohara; Ryo Mukai; Shinji Ueno; Hideo Akiyama
Journal:  Case Rep Ophthalmol Med       Date:  2021-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.